{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T13:45:48Z","timestamp":1743860748147,"version":"3.38.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Low-dose methotrexate has been proposed as therapy for patients with severely disabling psoriasis and psoriatic arthritis. However, it can be associated with severe toxicity, such as pancytopenia, characterized by anemia (hemoglobin level &lt;13 g\/dL in men), thrombocytopenia (platelet count &lt;150 \u00d7 109\/L), and neutropenia or agranulocytosis (neutrophil count &lt;1.5 \u00d7 109\/L and 0.5 \u00d7 109\/L, respectively). Here, we report a challenging clinical scenario characterized by pancytopenia and acute renal failure to inform clinicians about potential drug\u2013drug interactions and subclinical renal insufficiency.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001297","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T13:00:08Z","timestamp":1734440408000},"page":"196-198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Misleading Renal Function Evaluation Leading to Severe Methotrexate-Induced Toxicity"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-7301","authenticated-orcid":false,"given":"Manon","family":"Launay","sequence":"first","affiliation":[{"name":"M\u00e9decine Intensive R\u00e9animation G, Centre r\u00e9gional de Pharmacovigilance, CHU Saint-Etienne, Saint Priest en Jarez, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Vogrig","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019H\u00e9matologie, CHU de Saint-Etienne, Saint Etienne, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Damin-Pernik","sequence":"additional","affiliation":[{"name":"Centre r\u00e9gional de Pharmacovigilance, CHU Nord de St Etienne, Saint Etienne, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Jean Monnet, Service de Rhumatologie, CHU Saint-Etienne, INSERM, Mines Saint Etienne, Saint-\u00c9tienne, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Perinel-Ragey","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Jean Monnet, M\u00e9decine Intensive R\u00e9animation G, CHU Saint-Etienne, INSERM, Mines Saint Etienne, Saint-\u00c9tienne, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Ure\u00f1a","year":"1996","journal-title":"Arthritis Rheum."},{"key":"R2-20250314","first-page":"679580","article-title":"Methotrexate induced pancytopenia","volume":"2014","author":"Gonzalez-Ibarra","year":"2014","journal-title":"Case Rep Rheumatol."},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","article-title":"The antifolates","volume":"26","author":"Visentin","year":"2012","journal-title":"Hematol Oncol Clin North Am."},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"e0154744","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One"},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/jcm8040515","article-title":"How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?-MTX in the treat-to-target strategy","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med."},{"issue":"suppl 3","key":"R7-20250314","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1007\/s11739-012-0802-0","article-title":"Hypoalbuminemia","volume":"7","author":"Gatta","year":"2012","journal-title":"Intern Emerg Med."},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/s10165-010-0315-5","article-title":"Elevated level of serum cystatin-C concentration is a useful predictor for myelosuppression induced by methotrexate for treatment of rheumatoid arthritis","volume":"20","author":"Hayashi","year":"2010","journal-title":"Mod Rheumatol."},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00277-016-2795-7","article-title":"Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia","volume":"95","author":"Reiss","year":"2016","journal-title":"Ann Hematol."},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/1756-185X.13004","article-title":"Methotrexate-induced pancytopenia: a case series of 46 patients","volume":"20","author":"Ajmani","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/bdd.2091","article-title":"Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3","volume":"38","author":"Narumi","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"R14-20250314","first-page":"271","article-title":"Effect of furosemide on urinary acidification in distal renal tubular acidosis","volume":"104","author":"Rastogi","year":"1984","journal-title":"J Lab Clin Med."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:02:06Z","timestamp":1741964526000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001297","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"2024-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}